Welcome to our dedicated page for Theralase Technologies news (Ticker: TLTFF), a resource for investors and traders seeking the latest updates and insights on Theralase Technologies stock.
Theralase Technologies Inc. reports company developments as a clinical-stage pharmaceutical developer of energy-activated small molecules for the destruction of cancer, bacteria and viruses. Its updates center on Ruvidar® (TLD-1433), including clinical and regulatory disclosures tied to non-muscle invasive bladder cancer and research into antiviral mechanisms such as HSV-1 inactivation.
Recurring announcements also cover operating and financial results, non-brokered private placements, line-of-credit financing, capital-structure disclosure, governance matters and development collaborations. The company’s news commonly links research progress with funding needs, regulatory pathways, intellectual-property considerations and commercialization risks for its small-molecule drug formulations.
Theralase Technologies (TLTFF) has announced promising interim clinical data showing improvements in both motor and non-motor function for Parkinson's Disease (PD) patients treated with their TLC-2400 Cool Laser Therapy (CLT) system.
In a triple-blind, randomized controlled study at the University of Windsor, patients received 7 treatments over 3 weeks using either active or placebo CLT systems. Key findings include:
- 11% increase in cognitive assessment scores with active treatment vs 4% with placebo
- 14% improvement in brain blood flow with active treatment vs 1% with placebo
- 19% improvement in fine motor control with active treatment vs 6% with placebo
- 9% improvement in orthostatic tolerance with active treatment vs no change with placebo
The study demonstrates that Theralase's CLT technology can non-invasively penetrate the human skull, promoting anti-inflammatory responses and stimulating dopamine production. This research is particularly significant as PD affects 1 million Americans, with treatment costs reaching $52 billion annually.
Theralase Technologies (TLTFF) has announced significant breakthroughs in treating Non-Hodgkin's Lymphoma (NHL) using their lead compound Rutherrin®. In a preclinical study, Rutherrin® demonstrated effective destruction of NHL when combined with Metformin and radiation in an animal model.
The research utilized A20 mouse lymphoma cells in a highly aggressive tumor model. The treatment protocol involved:
- Rutherrin® administered intravenously 3 times per week
- Daily Metformin injections
- Radiation 5 times per week
The most notable results came from the trimodal therapy combining all three treatments, which led to the best overall response, including one case of complete tumor regression with the mouse remaining tumor-free. NHL represents a significant market opportunity, with global market estimates reaching $16.5 billion by 2031. The disease affected approximately 544,000 new cases globally in 2020, resulting in 260,000 deaths.
Theralase Technologies (TSXV:TLT)(OTCQB:TLTFF) has successfully validated previous University of Manitoba research, demonstrating that Ruvidar™ is safe and effective in treating Herpes Simplex Virus Type 1 (HSV-1) in an animal model.
The research involved Balb/C mice infected with human HSV-1 virus. A 1% Ruvidar solution was applied topically to developed lesions once daily for 4 days, resulting in complete healing of the HSV-1 cutaneous lesions.
This breakthrough comes amid significant market opportunity, with the global HSV treatment market valued at $2.5 billion in 2023 and expected to grow at 8.1% CAGR from 2024 to 2030. Currently, an estimated 3.8 billion people under age 50 globally have HSV-1, while 520 million aged 15-49 have HSV-2. North America holds the largest market share at 32.4%.
Based on these successful results, Theralase plans to develop both a vaccine and therapeutic for HSV prevention and treatment, with clinical development to follow.
Theralase Technologies has validated previous University of Manitoba research, demonstrating that Ruvidar™ is safe and effective in treating Herpes Simplex Virus Type 1 (HSV-1) in an animal model. The research showed complete healing of HSV-1 cutaneous lesions in Balb/C mice after four days of treatment with a 1% Ruvidar solution.
The global HSV treatment market was valued at $2.5 billion in 2023, with an expected CAGR of 8.1% from 2024 to 2030. North America holds the largest market share at 32.4%. An estimated 3.8 billion people under age 50 globally have HSV-1, while 520 million people aged 15-49 have HSV-2.
Based on these successful results, Theralase plans to develop both a vaccine and therapeutic for HSV prevention and treatment, with clinical development to follow.
Theralase Technologies (TSXV:TLT)(OTCQB:TLTFF) announced breakthrough research from the University of Manitoba demonstrating that non-light activated Ruvidar™ is more effective than acyclovir in treating Herpes Simplex Virus (HSV) post-infection. The research, conducted by Dr. Kevin Coombs, showed that Ruvidar™ inhibited HSV-1 replication at significantly lower concentrations compared to acyclovir, the current gold standard treatment.
The study revealed both additive and synergistic anti-HSV-1 effects when combination therapy was tested. Light-activated Ruvidar™ has previously shown even greater effectiveness in HSV inactivation. With over 90% of the human population infected with HSV, Theralase plans to develop both a vaccine and therapeutic for HSV prevention and treatment, with preclinical development currently underway.
Theralase Technologies (TSXV:TLT)(OTCQB:TLTFF) announced that its interim clinical data has been selected for presentation at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas. The presentation will focus on their Phase II clinical study of light-activated TLD-1433 for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.
The interim data shows promising safety and efficacy results, with some patients demonstrating a duration of response of 3+ years following a single treatment. The innovative Ruvidar™ technology aims to provide an alternative to radical cystectomy for patients who have exhausted standard treatment options.
The company plans to complete patient enrollment in 2025, submit clinical data to Health Canada and FDA in 2026, and aims for commercial availability by 2027, pending regulatory approval.
Theralase Technologies has launched three new US-based Clinical Study Sites for its bladder cancer registrational clinical study. The sites include Associated Medical Professionals of NY, Urology of Indiana, and Central Ohio Urology Group. The company's Phase II registration study for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer has enrolled and treated 75 patients to date.
Key clinical results show that 61.9% of patients demonstrated a Complete Response, with Total Response reaching 68.3%. For duration of response, 43.6% of treated patients maintained Complete Response for at least 12 months. The safety profile shows 100% of patients experienced no Serious Adverse Events related to the treatment. According to Kaplan Meier estimates, patients achieving Complete Response have a ≥53.0% chance of remaining cancer-free for 1 year, ≥35.8% for 2 years, and ≥24.9% for 3 years.
Theralase Technologies has launched a new clinical study site at St. Joseph's Healthcare Hamilton for its bladder cancer therapy. The company's Phase II registration study investigates RuvidarTM (TLD-1433) activated by the TLC-3200 Medical Laser System for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.
Key results from 75 enrolled patients show: 61.9% demonstrated Complete Response (CR), increasing to 68.3% when including Indeterminate Response. 43.6% of CR patients maintained response for 12 months, with some showing continued response at 24 and 36 months. The study reported 100% safety with no serious adverse events.
The company now operates 11 clinical sites across North America, with 4 more planned for Q4 2024/Q1 2025. Theralase is seeking partnering opportunities for international commercialization of Ruvidar™, targeting regulatory approval in 2026.
Theralase Technologies released its Q3 2024 financial statements, reporting a 12% year-over-year decrease in total revenue. The company's gross margin was 47% of revenue ($290,848), with cost of sales at 53% ($332,136). The net loss for the nine-month period was $3,337,995, with the Drug Division representing 84% of this loss. The company completed multiple non-brokered private placements throughout 2024, raising approximately $3.9 million. In Study II clinical trials, 61.9% of evaluable patients achieved Complete Response, with 43.6% maintaining response for at least 12 months. The company plans to complete enrollment in 2025 and aims for FDA and Health Canada approval by end of 2026.
Theralase Technologies, a clinical stage pharmaceutical company, has closed a non-brokered private placement offering, issuing 2,221,334 Units at $CAN 0.30 per Unit for total gross proceeds of $CAN 666,400. Each Unit includes one common share and one warrant, with warrants exercisable at $CAN 0.45 per share for 5 years. The proceeds will support the ongoing Phase II Non-Muscle Invasive Bladder Cancer clinical study, preclinical research of Rutherrin, working capital, and general corporate purposes. The securities are subject to a four-month hold period expiring March 16th, 2025.